Development of nuclear receptors as anthelmintic targets

Information

  • Research Project
  • 6485433
  • ApplicationId
    6485433
  • Core Project Number
    R44AI048937
  • Full Project Number
    2R44AI048937-02
  • Serial Number
    48937
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2001 - 23 years ago
  • Project End Date
    6/30/2004 - 20 years ago
  • Program Officer Name
    GOTTLIEB, MICHAEL
  • Budget Start Date
    7/1/2002 - 22 years ago
  • Budget End Date
    6/30/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/10/2002 - 22 years ago
Organizations

Development of nuclear receptors as anthelmintic targets

DESCRIPTION (Provided by applicant): Over one billion people worldwide are infected by parasitic nematodes that cause various debilitating nutritional, gastrointestinal, and other diseases. Many such infections are not curable with existing medications, and preventive vaccines are not yet feasible for these complex parasites. The long-term goal of this project is to identify new anti-nematode compounds that will fulfill this human health need. Nuclear receptor (NR) transcription factors are proven targets of effective and commercially successful drugs and insecticides, but have not yet been exploited as anthelmintic targets. Compounds that selectively interfere with the functions of NRs essential for nematode viability will provide leads for the development of novel anthelmintics for the control of important human parasitic nematode infections. The results of Phase I identified parasitic nematode orthologs of NRs that have essential functions in C. elegans and established a cell-based assay for chemical modulators of nematode NR activity. Phase II will exploit the knowledge and tools acquired during Phase I to deploy a proprietary battery of high-throughput screens for isolating compounds that alter nematode NR function. Secondary assays will be used to select those active compounds that are most promising for further development in Phase III. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    424255
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:424255\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CAMBRIA BIOSCIENCES, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    WOBURN
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01801
  • Organization District
    UNITED STATES